Up­dat­ed: Ab­b­Vie to ac­quire Im­muno­Gen for $10B in ban­ner year for AD­Cs

Ab­b­Vie plans to ac­quire Im­muno­Gen for $10.1 bil­lion, the com­pa­nies said Thurs­day morn­ing, in a deal that would ex­pand the Big Phar­ma’s pres­ence in the on­col­o­gy field and mark an ex­it for the 42-year-old Boston biotech.

The Chica­go-area com­pa­ny will pay $31.26 per share in cash to get its hands on Im­muno­Gen’s on­col­o­gy pipeline, which in­cludes Ela­here, the an­ti­body-drug con­ju­gate that’s ap­proved for cer­tain ovar­i­an can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER